Details for Patent: 7,838,531

Which drugs does patent 7,838,531 protect, and when does it expire?

Patent 7,838,531 protects ZOKINVY and is included in one NDA.

This patent has nine patent family members in six countries.

Summary for Patent: 7,838,531

Title:	Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis
Abstract:	Although it can be farnesylated, the mutant lamin A protein expressed in Hutchison Gilford Progeria Syndrome (HGPS) cannot be defarnesylated because the characteristic mutation causes deletion of a cleavage site necessary for binding the protease ZMPSTE24 and effecting defarnesylation. The result is an aberrant farnesylated protein (called "progerin") that alters normal lamin A function as a dominant negative, as well as assuming its own aberrant function through its association with the nuclear membrane. The retention of farnesylation, and potentially other abnormal properties of progerin and other abnormal lamin gene protein products, produces disease. Farnesyltransferase inhibitors (FTIs) (both direct effectors and indirect inhibitors) will inhibit the formation of progerin, cause a decrease in lamin A protein, and/or an increase prelamin A protein. Decreasing the amount of aberrant protein improves cellular effects caused by and progerin expression. Similarly, treatment with FTIs should improve disease status in progeria and other laminopathies. In addition, elements of atherosclerosis and aging in non-laminopathy individuals will improve after treatment with farnesyltransferase inhibitors.
Inventor(s):	Gordon; Leslie B. (Foxboro, MA), Collins; Francis S. (Rockville, MD), Glover; Thomas (Ypsilanti, MI), Glynn; Michael W. (Darien, CT), Capell; Brian C. (Rumson, NJ), Cox; Adrienne D. (Chapel Hill, NC), Der; Channing J. (Chapel Hill, NC)
Assignee:	The United States of America as represented by the Department of Health and Human Services (Washington, DC) N/A (Anne Arbor, MI) The Regents of the University of Michiga (Peabody, MA) Progeria Research Foundation, Inc. (Chapel Hill, NC) The University of North Carolina at Chapel Hill (N/A)
Application Number:	11/828,117
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 7,838,531

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Eiger Biopharms	ZOKINVY	lonafarnib	CAPSULE;ORAL	213969-001	Nov 20, 2020		RX	Yes	No						REDUCING THE RISK OF MORTALITY IN HUTCHINSON-GILFORD PROGERIA SYNDROME (HGPS)
Eiger Biopharms	ZOKINVY	lonafarnib	CAPSULE;ORAL	213969-002	Nov 20, 2020		RX	Yes	Yes						REDUCING THE RISK OF MORTALITY IN HUTCHINSON-GILFORD PROGERIA SYNDROME (HGPS)

International Family Members for US Patent 7,838,531

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	547536
Australia	2003301446
Canada	2501464
European Patent Office	1552020
European Patent Office	1853265